Data support further development of CYT-338 in relapsed/refractory multiple myeloma

AVENTURA, Florida and NATICK, Mass., June 10, 2022 /PRNewswire/ — Cytovia Therapeutics, Inc., a biopharmaceutical company enabling natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, today announced that new data ‘she presents at the annual congress of the European Hematology Association in ViennaAustria June 10e2022 is now available on the EHA and Cytovia websites.

For more details on in-person poster presentations, please see the following:

Session Title: Poster Session
Date and time of the session: Friday, June 10, 2022 – 4:30 p.m. – 5:45 p.m. CEST
Final abstract code: P842
Abstract link: 2Abrowseby %3D8%2Atrierby%3D1%2Asearch%3DNK

Summary: CYT-338 is a multifunctional tetravalent IgG1-like NK cell-engaging antibody with a novel FLEX linker that simultaneously binds CD38-expressing cells and NK cells via the activating receptor NKp46. The pharmacokinetics and pharmacodynamics of CYT-338 have been studied using in vitro and in vivo multiple myeloma models. CYT-338 showed 3-fold higher dose-dependent binding to CD38-expressing MM cell lines compared to daratumumab. Epitope mapping studies indicated that CYT-338 binds to a different CD38 epitope than daratumumab. CYT-338 showed greater dose-dependent cytolysis, degranulation, and NK cell-redirected cytokine production against MM1S cells compared to daratumumab. CYT-338 showed minimal immune subset depletion, NK cell fratricidal, and cytokine release compared to daratumumab in vitro. CYT-338 has been shown to inhibit tumor growth and improve survival in in vivo models of multiple myeloma. These results support the further development of CYT-338 as a therapeutic to target CD38 expressing multiple myeloma cells distinct from daratumumab.

About Cytovia Therapeutics
Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing many of the most challenging unmet medical needs in cancer. Cytovia is focused on harnessing the innate immune system by developing complementary and disruptive NK cell and NK-engaging antibody platforms. The company is developing three types of iPSC-derived (or iNK) cells: unedited iNK cells, TALEN® gene-modified iNK cells with improved function and persistence, and TALEN® gene-modified iNK cells with chimeric antigen receptors (CAR-iNK) to improve specific tumor targeting. The second complementary core technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia’s proprietary Flex-NK™ technology.

These two technology platforms are used to develop treatments for patients with solid tumors such as HCC and glioblastoma as well as hematological malignancies such as refractory multiple myeloma.

Based in Aventura, Florida, Cytovia has research and development labs in Natick, Massachusetts, and a GMP cell manufacturing facility in Puerto Rico. The company’s R&D work is complemented by scientific partnerships with Cellectis, CytoImmune, Hebrew University of JerusalemINSERM, the New York Stem Cell Foundation and the University of California at San Francisco (UCSF).

Cytovia recently formed CytoLynx Therapeutics, a strategic partnership focused on research and development, manufacturing and commercialization activities in Greater China and beyond.

Learn more about and follow us on Facebook, Twitter, LinkedIn, Youtubeand instagram.

About CD38
Differentiation cluster 38 (CD38) is a type II receptor membrane glycoprotein that plays a role in cell adhesion, migration, and signal transduction. Moreover, CD38 is an ectoenzyme involved in the generation of nucleotide metabolites, such as ADP-ribose which regulate cellular metabolism. CD38 is highly expressed in multiple myeloma (MM) on malignant plasma cells and is also moderately expressed on normal T, B, NK and myeloid cells. Antibodies targeting CD38, such as daratumumab and isatuximab, are FDA-approved for the treatment of MM as monotherapy and in combination.

Additional information and where to find it
Isleworth Healthcare Acquisition Corp. (“Isleworth”) (NASDAQ: ISLE) intends to file a registration statement on Form S-4 with the Securities Exchange Commission (the “SEC”), which will include a proxy statement/prospectus, which will be the proxy statement to be distributed to holders of Isleworth common stock in connection with its solicitation of proxies for the vote of Isleworth shareholders on the proposed business combination pursuant to a merger agreement and plan of Reorganization entered into on April 26, 2022, by and between Isleworth, Cytovia Holdings, Inc., the parent company of Cytovia Therapeutics (“Cytovia”), IHAC First Merger Sub Inc., a direct wholly-owned subsidiary of Isleworth, IHAC Second Merger Sub LLC, a direct, wholly owned subsidiary of Isleworth, and Isleworth Healthcare Sponsor I, LLC (the “Business Combination”) and other matters that may be described in the registration statement, as well si that the prospectus relating to the offer and sale of the securities to be issued within the framework of the Business Combination. Once the registration statement is declared effective, Isleworth will mail a definitive proxy statement/prospectus and other relevant materials to its shareholders. This communication does not contain all of the information to be taken into account regarding the Business Combination and is not intended to form the basis of an investment decision or any other decision relating to the Business Combination. Isleworth shareholders and other interested persons are advised to read, when available, the proxy statement/preliminary prospectus included in the registration statement and its amendments, together with the proxy statement /definitive prospectus and other documents filed in connection with the business combination, as these documents will contain important information about Cytovia, Cytovia Therapeutics, Isleworth and the business combination. When available, the definitive proxy statement/prospectus and other documents relevant to the business combination will be mailed to Isleworth shareholders on a record date to be determined to vote on the business combination. companies. Shareholders will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement and other documents filed with the SEC, free of charge, when available, on the SEC’s website at, or by directing a request to Isleworth’s secretary at 360 Central Avenue, First Central Tower, Suite #800, St. Petersburg, Florida 33701.

Participants in the solicitation
Isleworth, Cytovia and their respective directors, officers and other officers and employees, under SEC rules, may be considered participants in the solicitation of proxies from Isleworth stockholders in connection with the proposed transaction. . Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of directors and officers of Isleworth in Isleworth’s Annual Report on Form 10-K for the year ended December 31. 2021, which was filed with the SEC on March 29. , 2022. To the extent Isleworth’s securities holdings have changed since the filing of the Annual Report on Form 10-K, such changes have been or will be reflected in the ownership change statements on Form 4 filed with the SEC. . Information regarding persons who may, under SEC rules, be considered participants in the solicitation of proxies from Isleworth stockholders in connection with the proposed transaction will be set forth in the proxy statement/statement. information/prospectus for the proposed transaction when it becomes available. Information regarding the interests of Isleworth participants in the solicitation, which may, in some cases, differ from those of shareholders of Isleworth Healthcare Acquisition Corp. generally, will be set forth in the management proxy statement/information statement/prospectus relating to the proposed transaction when it becomes available.

Forward-looking statements
This press release may contain forward-looking statements, which can be identified by words such as “aims”, “anticipates”, “believes”, “could”, “estimates”, “expects”, “expects”, “aims”, “intends”, “may”, “plans”, “possible”, “potential”, “seeks”, “will” and variations of such words or similar expressions which are intended to identify statements forward-looking, although not all looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential of Cytovia’s FLEX-NK multifunctional engagement antibody and iNK cells. Cytovia may not achieve the plans, intentions or expectations disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements due to a variety of factors, including whether the outcome of preclinical studies will be predictive of clinical trial results. All forward-looking statements contained in this press release speak only as of the date hereof, and Cytovia expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of new information, future events, changes in circumstances or otherwise, except as otherwise required by law.

No offer or solicitation
This communication is for informational purposes only and does not constitute an offer to buy, or a solicitation of an offer to sell, subscribe or purchase, securities or the solicitation of a vote in any jurisdiction in accordance with the Consolidation of ‘Businesses or otherwise, nor shall any sale, issue or transfer of securities in any jurisdiction in violation of applicable law.

favicon.png?sn=FL85214&sd=2022-06-10 View original content for multimedia download: -at-eha-congress-2022-301565565.html

SOURCE Cytovia Therapeutic